Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

[1]  S. Surapaneni,et al.  Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects , 2011, Cancer Chemotherapy and Pharmacology.

[2]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British journal of pharmacology.

[3]  R. Obach,et al.  Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.

[4]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[6]  S. Mchugh,et al.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor‐alpha (TNF‐α) inhibition suggest drugs capable of selective gene regulation , 1997, Clinical and experimental immunology.

[7]  M. Frech,et al.  Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.

[8]  L. Sapinoso,et al.  Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. , 2010, Current cancer drug targets.

[9]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.